These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17038440)

  • 1. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.
    Sowden GL; Drucker DJ; Weinshenker D; Swoap SJ
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R962-70. PubMed ID: 17038440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus.
    Riediger T; Eisele N; Scheel C; Lutz TA
    Am J Physiol Regul Integr Comp Physiol; 2010 Apr; 298(4):R1061-7. PubMed ID: 20147608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
    Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
    Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxyntomodulin reduces expression of glucagon-like peptide 1 receptor in the brainstem of chickens.
    Moghaddam AG; Yaghoobi MM; Jonaidi H; Mahani MT; Sepehri H
    J Anim Physiol Anim Nutr (Berl); 2010 Aug; 94(4):422-8. PubMed ID: 19663977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral oxyntomodulin reduces food intake and body weight gain in rats.
    Dakin CL; Small CJ; Batterham RL; Neary NM; Cohen MA; Patterson M; Ghatei MA; Bloom SR
    Endocrinology; 2004 Jun; 145(6):2687-95. PubMed ID: 15001546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
    Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
    ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
    Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
    Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.
    Yamamoto H; Lee CE; Marcus JN; Williams TD; Overton JM; Lopez ME; Hollenberg AN; Baggio L; Saper CB; Drucker DJ; Elmquist JK
    J Clin Invest; 2002 Jul; 110(1):43-52. PubMed ID: 12093887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
    McKay NJ; Kanoski SE; Hayes MR; Daniels D
    Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
    Kosinski JR; Hubert J; Carrington PE; Chicchi GG; Mu J; Miller C; Cao J; Bianchi E; Pessi A; Sinharoy R; Marsh DJ; Pocai A
    Obesity (Silver Spring); 2012 Aug; 20(8):1566-71. PubMed ID: 22421924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling.
    Lockie SH; Heppner KM; Chaudhary N; Chabenne JR; Morgan DA; Veyrat-Durebex C; Ananthakrishnan G; Rohner-Jeanrenaud F; Drucker DJ; DiMarchi R; Rahmouni K; Oldfield BJ; Tschöp MH; Perez-Tilve D
    Diabetes; 2012 Nov; 61(11):2753-62. PubMed ID: 22933116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.